BioMarin's Vimizim gets FDA nod


BioMarin's (BMRN -0.5%) Vimizim becomes the 2nd treatment for Morquio A syndrome approved by the FDA this week. The nod isn't a surprise after nearly getting a near-unanimous thumbs up at the Ad Com two months ago.

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs